Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.

Al via il progetto #MiFidoDiTe: 42 km legati l'uno all'altra: una maratona a nuoto che parte da Vulcano

News - read more

Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis

News - read more

FDA grants Orphan Drug Designation for the use of teicoplanin in Staphylococcus aureus infections in cf patients.

RP announcement - read more
Syndicate content